메뉴 건너뛰기




Volumn 54, Issue 2, 2011, Pages 351-358

Comparison of competitive ligand-binding assay and bioassay formats for the measurement of neutralizing antibodies to protein therapeutics

Author keywords

Bioassay; CLB assay; Immunogenicity; Neutralizing antibodies

Indexed keywords

AER 001; CD40 ANTIGEN; CP 870893; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 4; NEUTRALIZING ANTIBODY; PROTEIN; RANIBIZUMAB; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

EID: 78650795075     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2010.08.029     Document Type: Article
Times cited : (34)

References (22)
  • 1
    • 41349116947 scopus 로고    scopus 로고
    • Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products
    • Koren E., Smith H.W., Shores E., et al. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J. Immunol. Meth. 2008, 333:1-9.
    • (2008) J. Immunol. Meth. , vol.333 , pp. 1-9
    • Koren, E.1    Smith, H.W.2    Shores, E.3
  • 2
    • 67349241946 scopus 로고    scopus 로고
    • Immunogenicity of biologically-derived therapeutics: Assessment and interpretation of nonclinical safety studies
    • Ponce R., Abad L., Amaravadi L., Gelzleichter T., Gore E., et al. Immunogenicity of biologically-derived therapeutics: Assessment and interpretation of nonclinical safety studies. Regul. Toxicol. Pharmacol. 2009, 54:164-182.
    • (2009) Regul. Toxicol. Pharmacol. , vol.54 , pp. 164-182
    • Ponce, R.1    Abad, L.2    Amaravadi, L.3    Gelzleichter, T.4    Gore, E.5
  • 3
    • 71749108118 scopus 로고    scopus 로고
    • Foundation review: nonclinical development of biopharmaceuticals
    • 23/24
    • Baumann A. Foundation review: nonclinical development of biopharmaceuticals. Drug Discov. Today 2009, 14:1112-1122. 23/24.
    • (2009) Drug Discov. Today , vol.14 , pp. 1112-1122
    • Baumann, A.1
  • 5
    • 9644287732 scopus 로고    scopus 로고
    • A risk-based approach to immunogenicity concerns of therapeutic protein products - Part 1 - considering consequences of the immune response to a protein
    • Rosenberg A.S., Worobec A A risk-based approach to immunogenicity concerns of therapeutic protein products - Part 1 - considering consequences of the immune response to a protein. Biopharm. Int. 2004, 17:22-26.
    • (2004) Biopharm. Int. , vol.17 , pp. 22-26
    • Rosenberg, A.S.1    Worobec, A.2
  • 6
    • 10944231251 scopus 로고    scopus 로고
    • A risk-based approach to immunogenicity concerns of therapeutic protein products - Part 2 - considering host-specific and product specific factors impacting immunogenicity
    • Rosenberg A.S., Worobec A. A risk-based approach to immunogenicity concerns of therapeutic protein products - Part 2 - considering host-specific and product specific factors impacting immunogenicity. Biopharm. Int. 2004, 17:34-42.
    • (2004) Biopharm. Int. , vol.17 , pp. 34-42
    • Rosenberg, A.S.1    Worobec, A.2
  • 7
    • 16844367771 scopus 로고    scopus 로고
    • A risk-based approach to immunogenicity concerns of therapeutic protein products - Part 3 - effects of manufacturing changes in immunogenicity and the utility of animal immunogenicity studies
    • Rosenberg A.S., Worobec A. A risk-based approach to immunogenicity concerns of therapeutic protein products - Part 3 - effects of manufacturing changes in immunogenicity and the utility of animal immunogenicity studies. Biopharm. Int. 2005, 18:32-36.
    • (2005) Biopharm. Int. , vol.18 , pp. 32-36
    • Rosenberg, A.S.1    Worobec, A.2
  • 8
    • 34249684926 scopus 로고    scopus 로고
    • A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs
    • Shankar G., Pendley C., Stein K.E., et al. A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs. Nat. Biotechnol. 2007, 25:555-561.
    • (2007) Nat. Biotechnol. , vol.25 , pp. 555-561
    • Shankar, G.1    Pendley, C.2    Stein, K.E.3
  • 10
    • 78650769820 scopus 로고    scopus 로고
    • Evaluation of immunogenicity for pre-clinical and clinical investigations
    • Biopharm Knowledge Publishing, Westminister, London, N. Lyscom (Ed.)
    • Caras I. Evaluation of immunogenicity for pre-clinical and clinical investigations. Immunogenicity to Biologics 2007, Biopharm Knowledge Publishing, Westminister, London. N. Lyscom (Ed.).
    • (2007) Immunogenicity to Biologics
    • Caras, I.1
  • 11
    • 65649090964 scopus 로고    scopus 로고
    • Technology comparisons for anti-therapeutic antibody and neutralizing antibody assays in the context of an anti-TNF pharmacokinetic study
    • Loyet K.M., Deng R., Liang W.C., Wu Y., Lowman H.B., DeForge L.E. Technology comparisons for anti-therapeutic antibody and neutralizing antibody assays in the context of an anti-TNF pharmacokinetic study. J. Immunol. Methods 2009, 345:17.
    • (2009) J. Immunol. Methods , vol.345 , pp. 17
    • Loyet, K.M.1    Deng, R.2    Liang, W.C.3    Wu, Y.4    Lowman, H.B.5    DeForge, L.E.6
  • 12
    • 33746889823 scopus 로고    scopus 로고
    • A high throughput electrochemiluminescent cell-binding assay for therapeutic anti-CD20 antibody selection
    • Lu Y., Wong W.L., Meng Y.G. A high throughput electrochemiluminescent cell-binding assay for therapeutic anti-CD20 antibody selection. J. Immunol. Methods 2006, 314:74.
    • (2006) J. Immunol. Methods , vol.314 , pp. 74
    • Lu, Y.1    Wong, W.L.2    Meng, Y.G.3
  • 13
    • 3343015039 scopus 로고    scopus 로고
    • The role of the CD40 pathway in the pathogenesis and treatment of cancer
    • Eliopoulos A.G., Young L.S. The role of the CD40 pathway in the pathogenesis and treatment of cancer. Curr. Opin. Pharmacol. 2004, 4:360-367.
    • (2004) Curr. Opin. Pharmacol. , vol.4 , pp. 360-367
    • Eliopoulos, A.G.1    Young, L.S.2
  • 14
    • 0037277480 scopus 로고    scopus 로고
    • Prospects for CD40-directed experimental therapy of human cancer
    • Tong A.W., Stone M.J. Prospects for CD40-directed experimental therapy of human cancer. Cancer Gene Ther. 2003, 10:1-13.
    • (2003) Cancer Gene Ther. , vol.10 , pp. 1-13
    • Tong, A.W.1    Stone, M.J.2
  • 17
    • 33747619436 scopus 로고    scopus 로고
    • Development and validation of a quasi-quantitative bioassay for neutralizing antibodies against CP-870,893
    • Baltrukonis D.J., Finco-Kent D., Kawabata T.T., Poirier M., LeSauteur L. Development and validation of a quasi-quantitative bioassay for neutralizing antibodies against CP-870,893. J. Immunotoxicol. 2006, 3:157-164.
    • (2006) J. Immunotoxicol. , vol.3 , pp. 157-164
    • Baltrukonis, D.J.1    Finco-Kent, D.2    Kawabata, T.T.3    Poirier, M.4    LeSauteur, L.5
  • 18
    • 35348909044 scopus 로고    scopus 로고
    • Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies
    • Wenzel S., Wilbraham D., Fuller R., Burmeister Getz E., Longphre M. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 2007, 370:1422-1431.
    • (2007) Lancet , vol.370 , pp. 1422-1431
    • Wenzel, S.1    Wilbraham, D.2    Fuller, R.3    Burmeister Getz, E.4    Longphre, M.5
  • 19
    • 0038517976 scopus 로고    scopus 로고
    • Interleukin-4 and interluekin-13 signaling connections maps
    • Kelly-Welch A.E., Hanson E.M., Boothby M.R., Keegan A.D. Interleukin-4 and interluekin-13 signaling connections maps. Science 2003, 300:1527-1528.
    • (2003) Science , vol.300 , pp. 1527-1528
    • Kelly-Welch, A.E.1    Hanson, E.M.2    Boothby, M.R.3    Keegan, A.D.4
  • 20
    • 3142534409 scopus 로고    scopus 로고
    • Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products
    • Mire-Sluis A.R., Barrett Y.C., Devanarayan V., Koren E., Liu H., Maia M., et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J. Immunol. Meth. 2004, 289:1-16.
    • (2004) J. Immunol. Meth. , vol.289 , pp. 1-16
    • Mire-Sluis, A.R.1    Barrett, Y.C.2    Devanarayan, V.3    Koren, E.4    Liu, H.5    Maia, M.6
  • 21
    • 33745947584 scopus 로고    scopus 로고
    • Apelin, the ligand for the endothelial G-protein-coupled receptor, APJ, is a potent angiogenic factor required for normal vascular development of the frog embryo
    • Cox C.M., D'Agostino S.L., Miller M.K., Heimark R.L., Krieg P.A. Apelin, the ligand for the endothelial G-protein-coupled receptor, APJ, is a potent angiogenic factor required for normal vascular development of the frog embryo. Dev. Biol. 2006, 296:177-189.
    • (2006) Dev. Biol. , vol.296 , pp. 177-189
    • Cox, C.M.1    D'Agostino, S.L.2    Miller, M.K.3    Heimark, R.L.4    Krieg, P.A.5
  • 22
    • 0142011150 scopus 로고    scopus 로고
    • Angiogenic and angiostatic factors in the molecular control of angiogenesis
    • Distler J.H., et al. Angiogenic and angiostatic factors in the molecular control of angiogenesis. Q. J. Nucl. Med. 2003, 47:149-161.
    • (2003) Q. J. Nucl. Med. , vol.47 , pp. 149-161
    • Distler, J.H.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.